Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

18.2%

4 terminated/withdrawn out of 22 trials

Success Rate

73.3%

-13.2% vs industry average

Late-Stage Pipeline

77%

17 trials in Phase 3/4

Results Transparency

0%

0 of 11 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 3
17(81.0%)
Phase 2
4(19.0%)
21Total
Phase 3(17)
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT04031677Phase 3Recruiting

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

Role: collaborator

NCT06535893Phase 2Recruiting

Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer

Role: collaborator

NCT07190443Phase 3Recruiting

Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)

Role: collaborator

NCT06940791Phase 2Recruiting

Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)

Role: collaborator

NCT02781935Completed

Diffusion-Weighted MRI for Liver Metastasis

Role: collaborator

NCT02761070Phase 3Unknown

Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III

Role: collaborator

NCT04465968Phase 3Not Yet Recruiting

Efficacy and Safety of CRT, Durvalumab and Surgery for SST

Role: collaborator

NCT04288999Phase 3Recruiting

Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer

Role: collaborator

NCT00190554Phase 3Terminated

A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma

Role: lead

NCT00149279Phase 3Completed

A Trial to Evaluate Para-aortic Lymphadenectomy for Gastric Cancer

Role: lead

NCT00147147Phase 3Completed

Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-positive Gastric Cancer (JCOG9206-2)

Role: lead

NCT00145002Phase 3Completed

A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)

Role: lead

NCT00132613Phase 3Completed

Trial of Drainage With or Without Bleomycin Instillation for Malignant Pericardial Effusion

Role: lead

NCT00128037Phase 2Completed

Trial of Pre-operative Chemoradiotherapy Followed by Surgical Resection in Pancoast Tumors (JCOG 9806)

Role: lead

NCT00190476Phase 3Terminated

Elderly NSCLC/D vs DP (JCOG0207)

Role: lead

NCT00142350Phase 3Completed

A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer

Role: lead

NCT00190489Phase 3Completed

A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer

Role: lead

NCT00112086Phase 2Completed

OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206

Role: lead

NCT00132665Phase 3Completed

Trial to Evaluate Radiotherapy With or Without CBDCA in Elderly Patients With Non-Small Cell Lung Cancer (JCOG0301)

Role: lead

NCT00149201Phase 3Completed

A Study of 5-FU Versus MTX+5-FU in Gastric Cancer With Peritoneal Metastasis

Role: lead